HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva's Plan B One-Step OTC Application Puts FDA On The Spot

This article was originally published in The Tan Sheet

Executive Summary

Teva Pharmaceutical Industries asks FDA to allow over-the-counter sales of Plan B One-Step, starting the likely final leg of the emergency contraceptive's journey toward OTC status.

You may also be interested in...

Study Suggests Emergency Contraception Potential For Regular Use

Authors of a literature review suggest that 0.75 mg doses of levonorgestrel, currently used as an emergency contraceptive, may be safe and effective as a primary means of birth control in some populations but note that "rigorous new" safety and efficacy data would be needed to support such use.

Benefits, Pitfalls Of OTC Birth Control Apparent In Cross-Border Study

A pair of reports from a study of women who accessed birth control pills over the counter or by prescription showcases the benefits and challenges inherent in nonprescription oral contraceptives.

In Brief

EC drug goes nonprescription in Ireland

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts